Sahil Sharma

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1092172/publications.pdf

Version: 2024-02-01

50 papers	2,270 citations	186265 28 h-index	214800 47 g-index
51 all docs	51 docs citations	51 times ranked	2958 citing authors

#	Article	IF	Citations
1	Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. European Journal of Medicinal Chemistry, 2014, 77, 422-487.	5.5	348
2	Rational Approaches, Design Strategies, Structure Activity Relationship and Mechanistic Insights for Esterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2018, 18, 837-894.	2.4	115
3	Adapting to stress â€" chaperome networks in cancer. Nature Reviews Cancer, 2018, 18, 562-575.	28.4	105
4	Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3974-3979.	2.2	96
5	Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2014, 10, 23-71.	1.6	88
6	Triazole tethered C 5 -curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. European Journal of Medicinal Chemistry, 2016, 116, 102-115.	5.5	86
7	Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. Bioorganic and Medicinal Chemistry, 2019, 27, 3477-3510.	3.0	83
8	Xanthine oxidase inhibitors: a patent survey. Expert Opinion on Therapeutic Patents, 2011, 21, 1071-1108.	5.0	79
9	Design, Synthesis, Antimicrobial Evaluation, and Molecular Modeling Studies of Novel Indolinedioneâ€"Coumarin Molecular Hybrids. ACS Omega, 2019, 4, 8720-8730.	3.5	77
10	Design and Synthesis of Azaâ€Flavones as a New Class of Xanthine Oxidase Inhibitors. Archiv Der Pharmazie, 2013, 346, 7-16.	4.1	68
11	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 311-345.	5.0	67
12	Monocarbonyl Curcumin-Based Molecular Hybrids as Potent Antibacterial Agents. ACS Omega, 2019, 4, 11673-11684.	3.5	63
13	Screening of a library of 4-aryl/heteroaryl-4H-fused pyrans for xanthine oxidase inhibition: synthesis, biological evaluation and docking studies. Medicinal Chemistry Research, 2015, 24, 3334-3349.	2.4	60
14	Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2015, 23, 7165-7180.	3.0	60
15	Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 112, 298-346.	5.5	55
16	Silica supported BrÃ¶nsted acids as catalyst in organic transformations: A comprehensive review. Chinese Journal of Catalysis, 2015, 36, 520-549.	14.0	53
17	New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127477.	2.2	51
18	Vasicine and structurally related quinazolines. Medicinal Chemistry Research, 2013, 22, 1-15.	2.4	49

#	Article	IF	Citations
19	Synthesis and evaluation of naphthoflavones as a new class of non purine xanthine oxidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4192-4197.	2.2	49
20	Synthesis, screening and docking of fused pyrano[3,2- d]pyrimidine derivatives as xanthine oxidase inhibitor. European Journal of Medicinal Chemistry, 2017, 131, 14-28.	5.5	48
21	Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 495-500.	2.2	46
22	Xanthine oxidase inhibitors: patent landscape and clinical development (2015â€“2020). Expert Opinion on Therapeutic Patents, 2020, 30, 769-780.	5.0	34
23	Anticancer Hybrids- A Patent Survey. Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 303-339.	1.6	34
24	Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modelling studies. European Journal of Medicinal Chemistry, 2014, 85, 648-660.	5.5	33
25	A Chemical Biology Approach to the Chaperome in Cancerâ€”HSP90 and Beyond. Cold Spring Harbor Perspectives in Biology, 2020, 12, a034116.	5.5	32
26	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell Reports, 2020, 31, 107840.	6.4	32
27	Colchicine and its various physicochemical and biological aspects. Medicinal Chemistry Research, 2013, 22, 531-547.	2.4	30
28	Tubulin Inhibitors: A Patent Survey. Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 176-220.	1.6	30
29	Design, synthesis and evaluation of 2,4-diarylpyrano[3,2-c]chromen-5(4H)-one as a new class of non-purine xanthine oxidase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 730-736.	5.2	27
30	Synthesis and cytotoxicity studies of 3,5-diaryl N-acetyl pyrazolineâ€”isatin hybrids. Medicinal Chemistry Research, 2014, 23, 4337-4344.	2.4	26
31	Purine Analogues as Kinase Inhibitors: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2015, 10, 308-341.	1.6	26
32	Benzoflavone derivatives as potent antihyperuricemic agents. MedChemComm, 2019, 10, 128-147.	3.4	25
33	Chemotherapeutic Potential of Acridine Analogs: An Ample Review. Heterocycles, 2015, 91, 2043.	0.7	24
34	Synthesis of 1,2,3-triazole tethered bifunctional hybrids by click chemistry and their cytotoxic studies. Medicinal Chemistry Research, 2013, 22, 3160-3169.	2.4	20
35	Thiazole-5-carboxylic acid derivatives as potent xanthine oxidase inhibitors: design, synthesis, in vitro evaluation, and molecular modeling studies. Medicinal Chemistry Research, 2020, 29, 83-93.	2.4	19
36	Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 842-874.	1.7	19

#	Article	IF	Citations
37	Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 230-240.	1.7	15
38	Benzoflavones as cholesterol esterase inhibitors: Synthesis, biological evaluation and docking studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 850-854.	2.2	12
39	Structures of Hsp90Î± and Hsp90Î² bound to a purineâ€scaffold inhibitor reveal an exploitable residue for drug selectivity. Proteins: Structure, Function and Bioinformatics, 2019, 87, 869-877.	2.6	11
40	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications Biology, 2021, 4, 1333.	4.4	11
41	Topoisomerase I and II Inhibitors: A Patent Review. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 401-423.	1.6	10
42	Rational approaches for the design of various GABA modulators and their clinical progression. Molecular Diversity, 2021, 25, 551-601.	3.9	9
43	Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. Methods in Enzymology, 2020, 639, 289-311.	1.0	9
44	Donepezil-Inspired Multitargeting Indanone Derivatives as Effective Anti-Alzheimerâ€™s Agents. ACS Chemical Neuroscience, 2022, 13, 733-750.	3.5	9
45	Bisubstrate-Type Chemical Probes Identify GRP94 as a Potential Target of Cytosine-Containing Adenosine Analogs. ACS Chemical Biology, 2020, 15, 952-961.	3.4	7
46	Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 288-315.	1.7	5
47	Aza Analogs of Flavones as Potential Antimicrobial Agents. Letters in Drug Design and Discovery, 2013, 10, 327-334.	0.7	5
48	Unanticipated Cleavage of 2-Nitrophenyl-Substituted N-Formyl Pyrazolines under Bechamp Conditions: Unveiling the Synthesis of 2-Aryl Quinolines and Their Mechanistic Exploration via DFT Studies. ACS Omega, 2018, 3, 18783-18790.	3.5	4
49	Microwave-assisted synthesis of 11-substituted-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one derivatives catalysed by silica supported fluoroboric acid as potent antioxidant and anxiolytic agents. Medicinal Chemistry Research, 2019, 28, 2200-2217.	2.4	3
50	Copper mediated coupling of 2-(piperazine)-pyrimidine iodides with aryl thiols using Cu(I)thiophene-2-carboxylate. Tetrahedron Letters, 2017, 58, 4525-4531.	1.4	2